ライフサイエンスコーパス: patients in

1 ate was associated with EVALI in a convenience sample of 51 patients in 16 states across the United States.

2 In total, 212 patients in 35 sites were treated; mean (SD) baseline PASI sc

3 Approximately 40% of patients in both exercise dosing regimens were classified as

4 g strategy (ILS) before PCI impacts on outcomes among these patients in contemporary practice remains unclear.

5 xtures to classify target diseases and predict mortality of patients in critical conditions.

6 The number of patients in each category was: 1098 (>=2-<=12 months), 686 (>

7 Among patients in hospitals that introduced CCRT, the relative risk

8 After hip fracture repair, patients in hospitals with major decreases in LOS had a highe

9 al-acquired pneumonia (HAP) for can improve the outcomes of patients in intensive care units (ICUs).

10 Sepsis is the most common cause of death for patients in intensive care worldwide due to a dysregulated ho

11 ction and monitoring of pain outcomes and stratification of patients in interventional trials.

12 our machine learning model was able to identify EGFR-mutant patients in multiple validation sets with globally good accur

13 pegIFN administration, significantly higher proportions of patients in NAP groups had decreases in HBsAg to below 1 IU/m

14 , we generate 649 SARS-CoV-2 genome sequences from infected patients in New Zealand with samples collected during the 'fi

15 ge acquisition method for capturing RBC images from the SCD patients in normoxia and hypoxia conditions.

16 Among 61 (37.0%) patients in primary prevention, the annual rate of appropriat

17 ted with intra-arrest transport (exposed) were matched with patients in refractory arrest (at risk of intra-arrest transp

18 ivation of different leukocyte subsets in COVID-19-infected patients in relation to disease severity.

19 A cutoff value of 50 points identified patients in remission with the highest level of specificity (

20 or moderate local reactions) were reported for 51.0% of the patients in the 300 IR group and 14.9% in the placebo group.

21 f 426 patients in the secukinumab group and six (1%) of 427 patients in the adalimumab group had serious infections.

22 Treatment-related deaths occurred in two (<1%) patients in the atezolizumab group (autoimmune hepatitis rela

23 ical response rate was lower than that frequently quoted to patients in the clinic.

24 received prebiotic or symbiotic preparations, whereas 1369 patients in the control arm received placebo or standard care

25 We matched patients in the early and late groups using propensity scores

26 Compared with controls, patients in the intervention group received significantly low

27 h mRS 0-3 at 90 days according to treatment (28 [42%] of 66 patients in the intervention group vs 21 [32%] of 65 in the c

28 of 453 patients in the nivolumab group and 111 [25%] of 453 patients in the ipilimumab group) of 302 anticipated deaths o

29 For the LGI1-IgG seropositive subgroup, 6 of 8 patients in the IVIG group were responders, compared to zero

30 .1-5.5) over the study period, with the highest increase in patients in the most-deprived quintile.

31 With 211 (100 [22%] of 453 patients in the nivolumab group and 111 [25%] of 453 patients

32 % of the patients in the tocilizumab group and 21.2% of the patients in the placebo group were still receiving supplement

33 60 (57%) of 104 patients in the placebo group, 63 (66%) of 96 in the ixekizum

34 e open-label period, more rapid progression was noted among patients in the placebo-edaravone arm than among those in the

35 OCT scans improved by 1 step in 10 patients in the PPV group.

36 d in 101 (8.7%) patients in the ticagrelor and in 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95%

37 Three patients in the RMA group developed relapse.

38 Seven (2%) of 426 patients in the secukinumab group and six (1%) of 427 patient

39 ctively, the 5-year overall survival estimate of the 16 062 patients in the study cohort was 62.3% (95% CI 59.7-64.4).

40 kidney disease to facilitate best practices for supporting patients in the successful management of their kidney health.

41 The primary endpoint was reached in 101 (8.7%) patients in the ticagrelor and in 73 (6.3%) patients in the p

42 At 14 days, 24.6% of the patients in the tocilizumab group and 21.2% of the patients i

43 ere determined in 3-year intervals among prevalent dialysis patients in the United States between 1995 and 2012.

44 al membrane oxygenation to support critically ill, poisoned patients in the United States is increasing, driven primarily

45 Among patients in the University of North Carolina Center for AIDS

46 The objective response rate was 69% (95% CI 53-82; 31 of 45 patients) in the EZH2(mut) cohort and 35% (23-49; 19 of 54 pa

47 patients) in the EZH2(mut) cohort and 35% (23-49; 19 of 54 patients) in the EZH2(WT cohort.) Median duration of response

48 llected between 20 February and 15 March 2020 from infected patients in Washington state in the United States.

49 N with 1,169,662 12-lead resting ECGs obtained from 253,397 patients, in which 99,371 events occurred.

50 We re-analysed 640 throat swabs collected from patients in Wuhan with influenza-like-illness from 6 October